Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Examining Use of Small-molecule Inhibitors in Preserving Fertility
Disease Discoveries

Examining Use of Small-molecule Inhibitors in Preserving Fertility

By Sarah PlumridgeMar 21, 2017
Share
Facebook Twitter Email
This photo of antral follicles is a way to measure ovarian reserve.
This photo of antral follicles is a way to measure ovarian reserve.

Northwestern Medicine scientists and collaborators demonstrated a way to use a clinically available, small-molecule inhibitor alongside conventional chemotherapy to preserve ovarian function and fertility in mouse models.

In a study published in the Proceedings of the National Academy of Sciences, the authors showed how this inhibitor blocked the activity of the mTOR pathway, which plays a role in cell growth and metabolism; when elements of the pathway are mutated or deregulated, it can cause tumor growth.

Women undergoing conventional chemotherapy typically experience an accelerated loss of their reserve of immature follicles in the ovary, leading to reduced fertility and sometimes complete infertility.

“We have harnessed the molecular mechanisms that regulate follicle dormancy and activation to protect the ovarian reserve and fertility in the face of chemotherapy-induced damage. The outlook for translating these findings from bench to bedside is promising because we used small molecule inhibitors of the mTOR pathway, and one of these is already clinically approved,” said co-author Francesca Elizabeth Duncan, PhD, research associate professor of Obstetrics and Gynecology and executive director of the Center for Reproductive Science. Kara Goldman, MD, ’12 GME, former resident in Obstetrics and Gynecology, was the first author of the study.

Francesca Elizabeth Duncan, PhD, research associate professor of Obstetrics and Gynecology and executive director of the Center for Reproductive Science, show that a small-molecule inhibitor can preserve fertility in mice, when administered as a co-treatment with conventional chemotherapy.
Francesca Elizabeth Duncan, PhD, research associate professor of Obstetrics and Gynecology and executive director of the Center for Reproductive Science, showed that a small-molecule inhibitor can preserve fertility in mice, when administered as a co-treatment with conventional chemotherapy.

In mice, the investigators demonstrated that administration of mTOR inhibitors as a pretreatment and co-treatment with chemotherapy preserved ovarian function, prevented the activation of immature follicles and maintained normal fertility.

While follicle counts were greater in mice treated with a combination of chemotherapy and mTOR inhibitors compared to mice who didn’t receive the inhibitors, total follicle counts were lower in all mice treated with chemotherapy.

The results of the study also indicated that it only took a small reduction in mTOR activity to preserve ovarian function and normal birth rates, suggesting the combination may be an effective treatment to preserving fertility during chemotherapy.

The authors note that future studies will need to examine the effects of this combination treatment on tumor growth, and determine optimal dosage levels and timing of administration.

The study was funded by the American Society for Reproductive Medicine, Foundation for Women’s Wellness, Center for Reproductive Health After Disease Grant P50 HD076188 from the National Centers for Translational Research in Reproduction and Infertility, Avon Foundation, and Breast Cancer Research Foundation.

Cancer Research Women's Health
Share. Facebook Twitter Email

Related Posts

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Comments are closed.

Latest News

Physician Assistant Students Embrace ‘Shades of Purple’

Jul 1, 2022

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.